Show simple item record

dc.contributor.authorAl Rahim, Md
dc.contributor.authorYoon, Yonejung
dc.contributor.authorDimovasili, Christina
dc.contributor.authorShao, Zhiping
dc.contributor.authorHuang, Qian
dc.contributor.authorZhang, Emily
dc.contributor.authorKezunovic, Nebojsa
dc.contributor.authorChen, Lei
dc.contributor.authorSchaffner, Adam
dc.contributor.authorHuntley, George W.
dc.contributor.authorUbarrechena Belandia, Iván ORCID
dc.contributor.authorGeorgakopoulos, Anastasios
dc.contributor.authorRobakis, Nikolaos K.
dc.date.accessioned2021-05-11T12:40:32Z
dc.date.available2021-05-11T12:40:32Z
dc.date.issued2020-07-20
dc.identifier.citationBrain Communications 2(2) : (2020) // Article ID 100es_ES
dc.identifier.issn2632-1297
dc.identifier.urihttp://hdl.handle.net/10810/51345
dc.description.abstractExcitotoxicity is thought to play key roles in brain neurodegeneration and stroke. Here we show that neuroprotection against excitotoxicity by trophic factors EFNB1 and brain-derived neurotrophic factor (called here factors) requires de novo formation of 'survival complexes' which are factor-stimulated complexes of N-methyl-D-aspartate receptor with factor receptor and presenilin 1. Absence of presenilin 1 reduces the formation of survival complexes and abolishes neuroprotection. EPH receptor B2- and N-methyl-D-aspartate receptor-derived peptides designed to disrupt formation of survival complexes also decrease the factor-stimulated neuroprotection. Strikingly, factor-dependent neuroprotection and levels of the de novo factor-stimulated survival complexes decrease dramatically in neurons expressing presenilin 1 familial Alzheimer disease mutants. Mouse neurons and brains expressing presenilin 1 familial Alzheimer disease mutants contain increased amounts of constitutive presenilin 1-N-methyl-D-aspartate receptor complexes unresponsive to factors. Interestingly, the stability of the familial Alzheimer disease presenilin 1-N-methyl-D-aspartate receptor complexes differs from that of wild type complexes and neurons of mutant-expressing brains are more vulnerable to cerebral ischaemia than neurons of wild type brains. Furthermore, N-methyl-D-aspartate receptor-mediated excitatory post-synaptic currents at CA1 synapses are altered by presenilin 1 familial Alzheimer disease mutants. Importantly, high levels of presenilin 1-N-methyl-D-aspartate receptor complexes are also found in post-mortem brains of Alzheimer disease patients expressing presenilin 1 familial Alzheimer disease mutants. Together, our data identify a novel presenilin 1-dependent neuroprotective mechanism against excitotoxicity and indicate a pathway by which presenilin 1 familial Alzheimer disease mutants decrease factor-depended neuroprotection against excitotoxicity and ischaemia in the absence of Alzheimer disease neuropathological hallmarks which may form downstream of neuronal damage. These findings have implications for the pathogenic effects of familial Alzheimer disease mutants and therapeutic strategies.es_ES
dc.description.sponsorshipThis work was supported by National Institutes of Health grants 2RF1AG008200-29; 2R01-NS047229; P50AG05138; and by Grant AARF-17-531426 of the Alzheimer's Association.es_ES
dc.language.isoenges_ES
dc.publisherOxfor University Presses_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.subjectpost-synaptic currentses_ES
dc.subjectneuronal survivales_ES
dc.subjectsurvival complexeses_ES
dc.subjecttrophic factorses_ES
dc.subjectexcitotoxicityes_ES
dc.subjectfocal cerebral-ischemiaes_ES
dc.subjectMMDA receptores_ES
dc.subjectsynaptic plasticityes_ES
dc.subjectneurotrophic factores_ES
dc.subjectsignaling pathwayses_ES
dc.subjectoxidative stresses_ES
dc.subjectcalcium influxes_ES
dc.subjectA-betaes_ES
dc.subjectbraines_ES
dc.subjectsecretasees_ES
dc.titlePresenilin1 familial Alzheimer disease mutants inactivate EFNB1- and BDNF-dependent neuroprotection against excitotoxicity by affecting neuroprotective complexes of N-methyl-d-aspartate receptores_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holderThe Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.comes_ES
dc.rights.holderAtribución-NoComercial 3.0 España*
dc.relation.publisherversionhttps://academic.oup.com/braincomms/article/2/2/fcaa100/5873867es_ES
dc.identifier.doi10.1093/braincomms/fcaa100


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Except where otherwise noted, this item's license is described as The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com